An observational study in Hypertension, sponsored by Boehringer Ingelheim. Completed. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2014-09-17.
Sponsored by Boehringer Ingelheim · Observational
The primary objective was to evaluate the effect of the treatment with Micardis® or MicardisPlus® on blood pressure. Secondary objectives were the effect of Micardis® / MicardisPlus® on metabolic parameters (triglycerides, cholesterol, LDL blood glucose, insulin Homeostasis Model Assessment (HOMA)-index and HbA1c) in patients with essential hypertension and diabetes mellitus
6,689 studies on the registry are indexed under Hypertension; 965 are open to participants now.
This study's enrollment of 1,527 is above the median of 210 across 1,359 observational studies indexed under Hypertension.
Browse Hypertension studies →Boehringer Ingelheim is the lead sponsor of 2,245 studies on the registry; 58 are open to participants now.
Of its 162 completed or terminated interventional studies of FDA-regulated products, 116 (72%) have results posted.
Counted across the registry records on this site, refreshed daily.
Outpatients with hypertension and diabetes mellitus
Exclusion Criteria:
Drug: Micardis® · Drug: MicardisPlus®
Change from Baseline in systolic blood pressure (SBP)
Time frame: Baseline, after 6 months
Change from Baseline in diastolic blood pressure (DBP)
Time frame: Baseline, after 6 months
Assessment of efficacy by investigator on a 6-point scale
Time frame: after 6 months
Assessment of metabolic effect on a 3-point scale
Time frame: after 6 months
Change from Baseline in laboratory parameters
Metabolic parameters - Triglyceride, total cholesterol, blood glucose, insulin, HOMA-Index, HbA1c
Time frame: Baseline, after 6 months
Assessment of tolerability by investigator on a 5-point scale
Time frame: after 6 months
Number of patients with adverse events
Time frame: up to 6 months
No study locations are listed for this record.
This study is completed, as verified in Sep 2014. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Boehringer Ingelheim